IMCYSE
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eli... minate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
IMCYSE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Liège, Liege, Belgium
Country:
Belgium
Website Url:
http://www.imcyse.com
Total Employee:
11+
Status:
Active
Total Funding:
55.9 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Font Awesome Apache Euro
Current Employees Featured
Founder
Investors List
Biogenosis
Biogenosis investment in Series B - Imcyse
Epimède SA
Epimède SA investment in Series B - Imcyse
Pfizer
Pfizer investment in Series B - Imcyse
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - Imcyse
S.R.I.W.
S.R.I.W. investment in Series B - Imcyse
University of Leuven
University of Leuven investment in Series B - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
W.IN.G
W.IN.G investment in Grant - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
Belfius Bank
Belfius Bank investment in Debt Financing - Imcyse
Official Site Inspections
http://www.imcyse.com Semrush global rank: 2.8 M Semrush visits lastest month: 5.78 K
- Host name: cluster006.ovh.net
- IP address: 213.186.33.17
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Imcyse" on Search Engine
Imcyse - specific active immunotherapeutics
Transforming the treatment. of severe autoimmune diseases. Imcyse is a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies. Focused on …See details»
About us - Imcyse
About us. Committed to transforming the treatment of severe, chronic autoimmune diseases. From a discovery made at the Catholic University of Leuven (KUL), Imcyse …See details»
Pipeline - Imcyse
The Company’s robust pipeline currently comprises clinical-stage programs in Type 1 diabetes and Multiple sclerosis as well as pre-clinical programs in Neuromyelitis optica, …See details»
Imcyse - Crunchbase Company Profile & Funding
Legal Name Imcyse SA. Company Type For Profit. Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active …See details»
Imcyse appoints new Scientific Advisory Board and opens new ...
Liège, Belgium, June 24, 2021 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for …See details»
News & Events - Imcyse
June 24, 2021. INNODIA is ready for a new phase – clinical trials. Read more. February 17, 2021. Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer …See details»
Technology - Imcyse
Imotopesâ„¢ also induce memory cytolytic CD4+ T cells, which provide long-lasting treatment effects with infrequent dosing, like a vaccine. Broad applicability. In addition to autoimmune diseases, Imcyse’s technology …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2
LIÈGE, Belgium, April 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and …See details»
Imcyse Announces Completion of Enrollment in Phase 1 Clinical …
Liège, Belgium, September 13, 2023 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for …See details»
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT …
Mar 1, 2023 LIEGE, BELGIUM / ACCESSWIRE / March 1, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and …See details»
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT …
Liège, Belgium, March 1, 2023 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for …See details»
Imcyse Reports Positive Immune Response from Interim Analysis …
LIÈGE, Belgium, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and …See details»
Imcyse Announces Start of Phase 1b/2a IMPACT Study in …
Feb 3, 2021 LIEGE, BELGIUM / ACCESSWIRE / February 3, 2021 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active …See details»
Imcyse Announces Completion of Enrollment in Phase 1 Clinical …
Sep 13, 2023 LIEGE, BELGIUM / ACCESSWIRE / September 13, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of …See details»
Imcyse - Funding, Financials, Valuation & Investors - Crunchbase
Organization. Imcyse. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Funding Rounds 4. Total Funding Amount. …See details»
Imcyse Enters into Research Collaboration and License …
Feb 2, 2021 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of …See details»
Imcyse - Contacts, Employees, Board Members, Advisors
Organization. Imcyse. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 6. Contacts 2. About. Imcyse …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 …
LIÈGE, Belgium, April 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and …See details»
Imcyse - Crunchbase
Companies like Imcyse include Excision BioTherapeutics, Inovio Pharmaceuticals, and Agenus. Jounce Therapeutics Cambridge , Massachusetts , United States 152 Contacts …See details»
Imcyse | CipherBio
Imcyse | CipherBio. Biotech 2010. Submit Changes. Liege, Belgium http://www.imcyse.com. Developing disease specific immune therapies to treat severe, …See details»